GemVax Presents at Europe's Largest ALS Conference... Expects Indication Expansion

GemVax & KAEL presented the preclinical results of GV1001 at Europe's largest amyotrophic lateral sclerosis (ALS) conference.

On June 9, GemVax announced that the preclinical trial results of GV1001 for ALS were unveiled at the 'European Network to Cure ALS (ENCALS) 2025'.

ALS is an intractable neurodegenerative disease for which there is currently no fundamental cure. ENCALS is a prestigious international conference that brings together researchers from across Europe with the goal of developing a fundamental treatment for ALS. It serves as a platform to share the latest research trends and achievements in the ALS field. This year, the conference was held in Turin, Italy from June 3 to June 6 (local time).

At the conference, GemVax presented significant improvements in motor performance and a marked increase in survival rates observed after administering GV1001 to ALS animal models. The company also disclosed the results of its analysis of the mechanism of action.

This outcome is the result of joint research between GemVax's in-house research team, including advisor Kim Sangjae, and leading domestic research institutions. It is noteworthy as it represents a combination of scientific expertise from both industry and academia in the development of therapeutics for neurodegenerative diseases.

By confirming meaningful therapeutic potential in the ALS preclinical study, GemVax completed a patent application last month for the 'prevention and treatment of ALS with GV1001'. Following its intellectual property applications for Alzheimer's disease and progressive supranuclear palsy (PSP), the company has now filed for ALS as well, thereby laying the groundwork for expanding indications in the field of neurodegenerative diseases.

A GemVax official stated, "This is a meaningful achievement that provides scientific evidence for the therapeutic potential of GV1001 in ALS," and added, "It suggests that GV1001 could expand its indications in neurodegenerative diseases from Alzheimer's disease and PSP to ALS."

The official continued, "Through this conference, we actively shared our research results with leading researchers in the ALS field worldwide, and we plan to continue research aimed at expanding the indications of GV1001 to include ALS."

Last year, GemVax completed the first-ever domestic phase 2 clinical trial for PSP. Based on these data, the company is preparing for a global phase 3 clinical trial. For its Alzheimer's disease therapeutic, another neurodegenerative disease, the company is smoothly conducting a global phase 2 clinical trial and expects to confirm the results within this year.

This content was produced with the assistance of AI translation services.